Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Biol Open ; 1(5): 458-66, 2012 May 15.
Artigo em Inglês | MEDLINE | ID: mdl-23213437

RESUMO

The membrane-anchored metalloproteinase-regulator RECK has been characterized as a tumor suppressor. Here we report that mice with reduced Reck-expression show limb abnormalities including right-dominant, forelimb-specific defects in postaxial skeletal elements. The forelimb buds of low-Reck mutants have an altered dorsal ectoderm with reduced Wnt7a and Igf2 expression, and hypotrophy in two signaling centers (i.e., ZPA and AER) that are essential for limb outgrowth and patterning. Reck is abundantly expressed in the anterior mesenchyme in normal limb buds; mesenchyme-specific Reck inactivation recapitulates the low-Reck phenotype; and some teratogens downregulate Reck in mesenchymal cells. Our findings illustrate a role for Reck in the mesenchymal-epithelial interactions essential for mammalian development.

2.
Oncogene ; 24(38): 5850-7, 2005 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-16007210

RESUMO

The membrane-anchored MMP-regulator RECK is down regulated in many solid tumors; the extent of RECK down regulation correlates with poor prognosis. Forced expression of RECK in tumor cells results in suppression of angiogenesis, invasion, and metastasis. Studies on the roles and the mechanisms of regulation of the RECK gene during normal development may therefore yield important insights into how the malignant behaviors of tumor cells arise and how they can be controlled. Our previous studies indicate that mice lacking RECK die around E10.5 with reduced tissue integrity. In the present study, we have found that in later stage wild-type embryos, RECK is abundantly expressed in skeletal muscles, especially in the areas where the myoblast differentiation factor MRF4 is expressed. Consistent with this finding, the RECK-promoter is activated by MRF4 in cultured cells. In contrast, a myoblast determination factor MyoD suppresses the RECK-promoter. Myoblastic cells lacking RECK expression give rise to myotubes at higher efficiency than the cells expressing RECK, indicating that RECK suppresses myotube formation. These findings suggest that MyoD down regulates RECK to facilitate myotube formation, whereas MRF4 up regulates RECK to promote other aspects of myogenesis that require extracellular matrix integrity.


Assuntos
Regulação da Expressão Gênica no Desenvolvimento/fisiologia , Glicoproteínas de Membrana/metabolismo , Desenvolvimento Muscular/fisiologia , Músculo Esquelético/embriologia , Músculo Esquelético/metabolismo , Animais , Western Blotting , Proteínas Ligadas por GPI , Hibridização In Situ , Metaloproteinases da Matriz/metabolismo , Glicoproteínas de Membrana/genética , Camundongos , Fibras Musculares Esqueléticas/metabolismo , Proteína MyoD/metabolismo , Fatores de Regulação Miogênica/metabolismo , Regiões Promotoras Genéticas
3.
Cancer Lett ; 179(1): 87-93, 2002 May 08.
Artigo em Inglês | MEDLINE | ID: mdl-11880186

RESUMO

3-Nitrotyrosine (3-NT), a product of peroxynitrite reaction, is abundantly observed in hepatocytes adjacent to human metastatic colorectal carcinoma. To elucidate its biological significance, we undertook to identify nitric oxide (NO)-producing cells and apoptosis under oxidative stress. We observed strong inducible NO-synthase (iNOS) immunoreactivity in the hepatocytes adjacent to metastatic tumor, revealing an identical pattern to 3-NT immunostaining. Furthermore, intense 3-NT immunostaining of hepatocytes was associated with apoptosis whereas carcinoma cells near those hepatocytes presented high proliferating-cell nuclear antigen. Our results suggest that contact of metastatic tumor induces apoptosis in adjacent hepatocytes through peroxynitrite, thus permitting the proliferation of cancer cells.


Assuntos
Adenocarcinoma/secundário , Neoplasias Colorretais/patologia , Neoplasias Hepáticas/secundário , Nitratos/farmacologia , Oxidantes/farmacologia , Estresse Oxidativo/efeitos dos fármacos , Tirosina/análogos & derivados , Adenocarcinoma/metabolismo , Idoso , Apoptose , Divisão Celular , Neoplasias Colorretais/metabolismo , Feminino , Humanos , Técnicas Imunoenzimáticas , Neoplasias Hepáticas/metabolismo , Masculino , Pessoa de Meia-Idade , Óxido Nítrico/metabolismo , Óxido Nítrico Sintase/metabolismo , Óxido Nítrico Sintase Tipo II , Antígeno Nuclear de Célula em Proliferação/metabolismo , Espécies Reativas de Oxigênio/metabolismo , Tirosina/metabolismo
4.
Am J Pathol ; 160(2): 419-24, 2002 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-11839561

RESUMO

Oxidative tissue damage has been shown to be associated with carcinogenesis. In human cancers p16(INK4A) is one of the most frequently mutated tumor suppressor genes. The present study used the ferric nitrilotriacetate (Fe-NTA)-induced rat renal carcinogenesis model to determine whether oxidative damage can cause specific allelic loss of p16 (INK4A). By the use of fluorescent in situ hybridization in combination with imprint cytology at single-cell resolution, we found that the number of renal tubular cells with aneuploidy (1 or 3 signals) at the p16(INK4A) locus was significantly and specifically increased (1 week, 37.2 +/- 2.3%; 3 weeks, 37.8 +/- 1.3% vs control, 22.5 +/- 1.9%; mean +/- SE, N = 8; P < 0.001 and P < 0.0001, respectively) after repeated intraperitoneal administration of 5 to10 mg of iron/kg in the form of Fe-NTA for 3 weeks. No increase in aneuploidy was observed at the loci of either the p53 or vhl tumor suppressor gene. Furthermore, the increase in the cells with 3 signals was followed by a continuous increase in those with 1 signal. Therefore, the p16 (INK4A) locus is specifically vulnerable to oxidative damage, leading to its allelic loss within weeks, presumably due to a deficiency in the replication of both the alleles.


Assuntos
Inibidor p16 de Quinase Dependente de Ciclina/genética , Genes Supressores de Tumor , Ferro/metabolismo , Neoplasias Renais/genética , Ácido Nitrilotriacético/análogos & derivados , Animais , Carcinógenos/toxicidade , Inibidor p16 de Quinase Dependente de Ciclina/metabolismo , Compostos Férricos/toxicidade , Humanos , Hibridização in Situ Fluorescente , Neoplasias Renais/induzido quimicamente , Neoplasias Renais/metabolismo , Masculino , Ácido Nitrilotriacético/toxicidade , Oxirredução , Ratos , Ratos Wistar
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA